Kazakhstan
Tuberculosis profile
| High MDR-TB burden |
Population  2013 16 million
Estimates of TB burden * 2013 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 1.6 (1.2–2) 9.5 (7.1–12)
Mortality (HIV+TB only) 0.11 (0.079–0.15) 0.68 (0.48–0.9)
Prevalence  (includes HIV+TB) 22 (7.6–43) 133 (46–263)
Incidence  (includes HIV+TB) 19 (12–27) 115 (75–165)
Incidence (HIV+TB only) 0.49 (0.4–0.59) 3 (2.5–3.6)
Case detection, all forms (%) 100 (70–150)    
Estimates of MDR-TB burden * 2013   New   Retreatment
% of TB cases with MDR-TB 25 (24–26) 55 (54–56)
MDR-TB cases among notified pulmonary
TB cases
2 700 (2 600–2 900) 3 800 (3 800–3 900)
TB case notifications 2013 New ** Relapse
Pulmonary, bacteriologically confirmed 7 942   5 190
Pulmonary, clinically diagnosed 2 931   891
Extrapulmonary 1 637   367
       
Total new and relapse 18 958    
Previously treated, excluding relapses 899    
Total cases notified 19 857    
Among 18 958 new and relapse cases:
511 (3%) cases aged under 15 years; male:female ratio: 1.7
Reported cases of RR-/MDR-TB 2013 New Retreatment Total **
Cases tested for RR-/MDR-TB 7 589 (96%) 7 297 (99%) 14 886
Laboratory-confirmed RR-/MDR-TB cases     6 411
Patients started on MDR-TB treatment     6 776
TB/HIV 2013 Number (%)
TB patients with known HIV status 18 104 (91)
HIV-positive TB patients 466 (3)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) 372 (80)
HIV-positive TB patients on antiretroviral therapy (ART) 271 (58)
HIV-positive people screened for TB 8 470  
HIV-positive people provided with IPT 662  
Treatment success rate (%)
New and relapse cases registered in 2012 86
Previously treated cases, excluding relapse, registered in 2012 78
HIV-positive TB cases, all types, registered in 2012 35
RR-/MDR-TB cases started on second-line treatment in 2011 74
XDR-TB cases started on second-line treatment in 2011  
Laboratories 2013  
Smear (per 100 000 population) 2.8
Culture (per 5 million population)  
Drug susceptibility testing (per 5 million population) 6.7
Sites performing Xpert MTB/RIF 19
Is second-line drug susceptibility testing available? Yes, in country
Financing TB control 2014  
National TB programme budget (US$ millions) 200
% Funded domestically 98%
% Funded internationally 2%
% Unfunded 0%
* Ranges represent uncertainty intervals
** Includes cases with unknown previous TB treatment history
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
   Prevalence

(Rate per 100 000 population per year)
Incidence graph
   Notified (new and relapse)   Incidence
   Incidence (HIV+TB only)

(Number of patients)
CPT ART graph
   HIV-positive TB patients
   on CPT   on ART

Treatment success rate (%)
tx success graph
   New   Retreatment
   New and relapse   Retreatment, excluding
relapse
   HIV-positive   RR-/MDR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Funded domestically__Funded internationally
__Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2015-07-28 Data: www.who.int/tb/data